Sartorius Stedim Biotech Reports Sales and Profitability Growth in Q3 2025

Significant Revenue Growth

During the first nine months of 2025, Sartorius Stedim Biotech recorded a significant increase in revenue, reaching EUR 2.195 billion, an increase of 10.2% at constant exchange rates (8.2% at actual exchange rates). This growth was primarily driven by its high-margin consumables business, which continued its strong growth trend. Underlying EBITDA increased by 21% to EUR 683 million, thus exceeding sales growth. The underlying EBITDA margin improved by 3.3 percentage points to 31.1%, up from 27.8% the previous year.

Expanding Product Portfolio

From January to September 2025, Sartorius Stedim Biotech expanded its product portfolio to enhance productivity in drug manufacturing, with new offerings for process intensification. In the third quarter, the company launched an improved filtration solution for monoclonal antibodies, reducing water costs and speeding up processes. It also entered into a partnership with the American startup Nanotein Technologies to develop and market innovative reagents for cell therapy. These initiatives are part of Sartorius's strategy to support its biopharmaceutical clients facing increasing pressures to accelerate timelines and reduce costs of innovative therapies.

Stabilization in Bioprocessing Equipment Activity

Despite a general reluctance from clients to invest, Sartorius Stedim Biotech's bioprocessing equipment activity shows signs of stabilization. All regions contributed positively to development, particularly the Americas and the Asia-Pacific region, which recorded double-digit growth. The company also refined its forecasts for 2025, now anticipating revenue growth of around 9% and an underlying EBITDA margin of about 31%. Sartorius Stedim Biotech continues to invest in its global research and production infrastructure, reaching EUR 276 million over the period. The net debt to underlying EBITDA ratio was reduced to 2.5.